What is Trelegy Ellipta?
Trelegy Ellipta is a prescription maintenance inhaler used once daily for the long-term treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults. It contains three active ingredients: fluticasone, umeclidinium, and vilanterol. This combination medicine helps to control symptoms and prevent them from occurring. Trelegy Ellipta is not intended for relieving sudden breathing problems. Patients should use a rescue inhaler for acute attacks.
How does Trelegy Ellipta work?
Trelegy Ellipta works by combining three medicines in one inhaler to help improve breathing. Fluticasone is an inhaled corticosteroid that reduces inflammation and swelling in the airways of the lungs. This makes them less sensitive to triggers. Umeclidinium is a long-acting muscarinic antagonist (LAMA). It works by keeping the airways open. Vilanterol is a long-acting beta-agonist (LABA). It relaxes the muscles around the airways. Together, these ingredients provide 24-hour relief from symptoms by keeping airways open and reducing inflammation.
Who is Trelegy Ellipta for?
Trelegy Ellipta is for adults who require long-term management of asthma or COPD. It is suitable for patients whose symptoms are not adequately controlled by other maintenance medications. This inhaler is intended for daily, long-term use to manage symptoms and prevent flare-ups. Trelegy Ellipta is not approved for use by anyone younger than 18 years old. It is also not a rescue inhaler and should not be used for sudden breathing emergencies.
Dosage and administration
Trelegy Ellipta should be taken as one inhalation once a day. You should use it at the same time each day to maintain its effects. It is important to follow your doctor’s prescribed dosage exactly. Do not use it more than once every 24 hours. The inhaler device is designed to deliver the correct dose automatically. After inhaling, rinse your mouth with water without swallowing to reduce the risk of oral thrush. If you miss a dose, take it as soon as you remember. Do not take more than one dose in a day.
Side effects
Trelegy Ellipta may cause side effects, though not everyone experiences them. You should talk to your doctor about potential risks. Common side effects can include:
- Headache
- Cough, sore throat, or hoarseness
- Runny or stuffy nose
- Upper respiratory tract infections
- Fungal infections in the mouth (oral thrush)
- Joint pain
Serious side effects are less common but require immediate medical attention. These can include pneumonia, especially in COPD patients. Watch for fever, chills, or increased mucus. Other serious effects involve heart problems, such as increased blood pressure or a fast heartbeat. Allergic reactions, like rash or swelling, are also possible. If you experience chest tightness or breathing trouble right after using the inhaler, seek help immediately.
Why buy from IsraelPharm?
IsraelPharm is a trusted source for authentic medications directly from Israel. We help you save on brand-name drugs like Trelegy Ellipta. Our licensed pharmacists ensure every prescription is handled with care. We provide reliable and discreet shipping to your door. You get the same high-quality medicine you would find in the US, but at a lower cost. Our customer service team is ready to assist you with your order. We are dedicated to making your medication affordable and accessible.
Consult your doctor before using Trelegy Ellipta. Common side effects may include:
- Headache
- Sore throat and hoarseness
- Runny or stuffy nose
- Upper respiratory tract infection
- Bronchitis
- Flu
- Mouth and throat fungal infections (thrush)
More serious side effects can occur. Seek medical help if you experience:
- Pneumonia symptoms (fever, chills, increased cough, increased mucus)
- Serious allergic reactions like rash or swelling
- Sudden breathing problems immediately after inhalation
- New or worsened heart problems or high blood pressure
- Eye problems like pain, blurred vision, or glaucoma
Trelegy Ellipta is indicated for the long-term, once-daily, maintenance treatment of:
- Asthma in patients aged 18 years and older.
- Chronic Obstructive Pulmonary Disease (COPD), including chronic bronchitis and/or emphysema.